Roth Capital Issues Pessimistic Forecast for REVB Earnings

Revelation Biosciences, Inc. (NASDAQ:REVB) – Investment analysts at Roth Capital reduced their FY2028 earnings per share estimates for shares of Revelation Biosciences in a research note issued on Wednesday, December 4th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of $2.03 for the year, down from their previous estimate of $2.06. The consensus estimate for Revelation Biosciences’ current full-year earnings is ($7.80) per share.

Revelation Biosciences Trading Down 3.4 %

REVB opened at $0.45 on Friday. Revelation Biosciences has a 12-month low of $0.42 and a 12-month high of $25.26. The company has a market cap of $1.95 million, a price-to-earnings ratio of -0.03 and a beta of 0.15. The stock has a fifty day simple moving average of $0.81 and a two-hundred day simple moving average of $1.28.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.